Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30% of men worldwide Treatment of PE typically involves pharmacotherapy, particularly when lifelong.
Although there are numerous reports on the off-label use of selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine (SSRI) (PMID: 23093633) the treatment of PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily delivery.
(PMID: 18360636) Pharmacological treatment of fibromyalgia.
different classes of drugs with different mechanisms of action are used off-label, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) (PMID: 21176430) The use of selective serotonin reuptake inhibitors during pregnancy or lactation is, to date, not promoted because of lack of safety documentation.
However, the off-label use of these drugs has been common for several years.
In the treatment of mood and anxiety disorders during pregnancy, the serotonin reuptake inhibitors are often preferred over tricyclic antidepressants because of their relatively few adverse effects and safety in overdose.
(PMID: 15643101).
